To evaluate specificity of our drug, flow cytometry based blocking assays were performed with HT-29 (EpCAM+, CD133−) and Caco-2 (EpCAM+, CD133+) colon carcinoma cell lines. This evidence concerns the gene PROM1 and colon carcinoma.